COMPANIES / **2024**



Paris Biotech Santé



Paris Biotech Santé

The reference for **health project** and **high-potential innovative** business support in France

Created over 20 years ago by Université Paris Cité, ESSEC, CENTRALESUPELEC, and INSERM, the Paris Biotech Santé incubator selects and supports the creation and development of innovative projects and companies in the specific sector of human health, covering areas such as pharmaceuticals, medical devices, e-health, and artificial intelligence…

Supported by the Ministry of Higher Education, Research, and Innovation, the City of Paris, and the Ile-de-France Region, **Paris Biotech Santé is committed** to advancing high-value projects based on evidence-based medicine and addressing identified needs for patients and healthcare professionals.

Individual and collective support at the service of your project

Are you looking to strengthen your team, develop a roadmap, build a business plan, define a financial strategy, and secure your initial funding? Paris Biotech Santé offers unique support combining individual guidance with a collective program, punctuated by regular workshops and meetings that promote the sharing of experiences and fostering of collaboration.

Paris Biotech Santé facilitates access to both dilutive and non-dilutive funding, notably **through two labels:** the Fonds parisien pour l'innovation (City of Paris) and InnovUp Incubation (Ile-de-France Region), as well as convertible bonds from BPI France through the **HealthTech Paris Consortium**.

Paris Biotech Santé relies on a flexible network of experts and entrepreneurs.

An on-site accommodation is possible in the heart of Paris, within the Faculty of Medicine - Cochin Campus - Université Paris Cité.

PARIS SANTE COCHIN represents an entrepreneurial pathway at the heart of the GHU Paris Centre.

In partnership with RIVP, Paris Biotech Santé is the preferred point of contact for selecting and supporting innovative healthcare companies that have already secured significant initial funding.

Would you like to establish yourself **in a stimulating environment close to key health innovation players? The Pépinière/Hôtel PARIS SANTE COCHIN offers 6,000 m² of offices and laboratories (L1 and L2) at Cochin Hospital. An opportunity** to collaborate with nearby clinical teams and research platforms.

Joining the community of entrepreneurs at PARIS BIOTECH SANTE means…

Gaining and contributing to a dynamic and collaborative ecosystem with over 50 innovative companies dedicated to health.

Collaborating with **public research, leading hospital structures** and **partners** of Paris Biotech Santé.

Contributing to **the commercialization of high-impact solutions to improve patients' lives, while also fostering job creation and economic growth.**

This document presents all the companies supported by Paris Biotech Santé in the incubator, the startup nursery, and the business hotel.




Incubator companies

- Pharmaceuticals
- Diagnostics and biomarkers
- Medical Technology or scientific instrumentation
- E-Health / Software & Mobile Apps / Connected Places & Objects
- Proximity services to patients and health professionals

Sector of activity
Pharmaceuticals

Team
Laila Quere
President
Tijani Gharbi
Managing Director

Activity
Aken Medical is positioned as a pioneer in revolutionizing cancer treatment by developing the next generation of radiotherapy. The company is currently developing a targeted therapy combining nanomedicine and radiation to enhance treatment effectiveness while improving patients' quality of life.
This innovative approach also includes theranostics, providing real-time imaging to optimize treatment efficacy.





Contact
laila.quere@akemedical.com
www.akenmedical.com

Sector of activity
Pharmaceuticals

Team
Dr. Mireille Laforge
CSO, Founder
Pr. Pierre Gressens
Clinical Advisor, Co-founder
Raphael De Saint-Exupéry
Advisor, Co-founder
Dr. Bruno Villoutreix
Drug Development Advisor

Activity
According to the World Health Organization, infectious diseases are among the three leading causes of death worldwide. ASTREMIHA Therapeutics is developping broad-spectrum antivirals, aimed at blocking viral replication and strengthening the immune system against infections. These next generation antivirals are very innovative and will address urgent and priority health needs such as AIDS and long COVID ; they will have both preventive and curative properties.



Contact
contact@astremiha.com
www.astremiha.com

Sector of activity
Medical Technology
or scientific instrumentation

Team
Philippe Mendels-Flandre
CEO
Mathieu Couade
CSO
Frédéric Giral
CTO


Activity
A pioneer in the automated exploration of vibrations of the surface of the thorax, AUSTRAL Dx is developing a contactless cardiopulmonary auscultation device assis ted by AI. Resulting from a collaboration between the Langevin Institute and Pitié-Salpêtrière, this device is a breakthrough innovation which responds to the strategic need to relieve congestion in emergency services and accessibility to medical imaging in medical deserts.

Contact
info@australdx.fr
www.australdx.fr

Sector of activity
Pharmaceuticals

Team
Yassine Taoufik
Marie-Ghislaine de Goer de Herve
Manon Dekeyser
Antoine Durrbach

Activity
BlueTheris develops predictive biomarkers and therapeutic solutions for human polyomavirus infections. Our therapeutic solutions are based on an innovative autologous and specific cell therapy approach.



Contact
contact@bluetheris.com
www.bluetheris.com

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Camille Martial
Managing Director
Vincent Vidmaire
President

Activity
Cérébro is a digital platform offering language rehabilitation applications to improve the quality and efficiency of care for patients suffering from stroke, head injury or neurodegenerative disease. Our solution, currently based on a BtoB model for speech therapists, is intended to become a platform directly accessible to cerebral palsy patients to intensify their care.

Contact
admin@lecerebro.com
www.lecerebro.com

Sector of activity
Diagnostics and biomarkers

Team
Geoffroy Poulet
CEO, Co-founder
Yoan Velut
CSO, Co-founder

Activity
CGenetix is a MedTech company offering an in vitro molecular diagnostic kit for kidney transplant patients.
The company's ultra-sensitive technology enables both early detection and characterization of graft rejection, enabling clinicians to personalize anti-rejection treatment and limit graft loss.





Contact
geoffroy.poulet@cgenetix.com
yoan.velut@cgenetix.com
www.cgenetix.com

Sector of activity


Diagnostics and biomarkers

Team

Guillaume Horreard
CEO
Margot Karlikow
CTO

Activity

En Carta develops a new generation of highly reliable diagnostics combining lab-grade tests with the simplicity of use of antigenic tests, enabling better care, everywhere. Our technological platform can be programmed for the detection of any DNA/RNA sequences. With several functional prototypes and a clinical trial – En Carta Diagnostics is the most robust and simple technology for point-of-care diagnostic.



Contact

guillaume.horreard@encarta.bio
www.encarta.bio

Sector of activity

E-Health / Software & Mobile Apps / Connected Places & Objects

Team

Pr. Anne Vanet
CEO
Dr. Nicolas Berti
CTO
Sarah Byron
CBO
Rachel Frizot
CAO

Activity

COVID Influenza cancer are global public health issues. At the crossroads of genetics, chemistry, drug designs and software, FAM! Is developing digital twins in cancer research, tracking down RNA virus variants to find new therapeutics solutions that are effective over the long term. It uses the appearance of mutations that makes life so difficult for patients against the disease itself, a challenge met by patent application. It is a UPCité/CNRS spin-off.



Contact

anne.vanet@u-paris.fr

Sector of activity

Diagnostics and biomarkers

Team

Gabriel Lerebours
CEO

Activity

Floating Genes is developing new molecular biology tools for the early detection of cancers in liquid biopsy. The company is initially focusing on digestive cancers (pancreas and colorectal). Its technology allows the detection of rare ctDNA in blood thanks to low depth high throughput sequencing (NGS).

Contact

gabriel.lerebours@floating-genes.com
www.floating-genes.com

Sector of activity

Medical Technology
or scientific instrumentation

Team

Emmanuelle Santos
President and Founder

Activity

Herapreg, which specializes in women's health, is dedicated to creating and marketing practical solutions using the benefits of compression. The brand has succeeded in designing Pelvinity: an innovative undergarment that offers real compression therapy to the pelvic floor. Thanks to its patented technology, it effectively relieves the uncomfortable sensations of pelvic and vulvar heaviness experienced by many women affected by vulvar varicosities, prolapse, pelvic congestion...





Contact

emmanuelle.santossouffir@herapreg.com
www.herapreg.com

Sector of activity

E-Health / Software & Mobile Apps / Connected Places & Objects

Team

Dr. Benjamin Benichou
Dental Surgeon and Coder,
Founder and Technical Manager
Dr. Ludovic Benichou
Maxillofacial Surgeon and Coder,
Founder and Technical Manager

Activity

laBoiteBleue creates tools and medical applications designed by caregivers for caregivers. Thanks to their dual skills as caregiver and computer coder, Drs BENICHOU offer tools whose ergonomics have been designed for real practical. The first product, cadsmile3d, allows the dental surgeon to design waxup proposals for their prosthetist modeled in 3D directly on the browser in a few minutes.



Contact

teamcadsmile@gmail.com
www.cadsmile3d.com

Sector of activity

Proximity services to patients and health professionals

Team

Nadia Mallet
President, Co-founder,
Product Director
Muriel Binn
Co-founder, Medical Director

Activity

Malinn aims at improving colorectal cancer screening by facilitating bowel preparation for colonoscopy. We offer patient support, from screening pathway initiation to colonoscopy realization, and provide healthy and tasty low-fiber meals, to improve adherence and tolerance to bowel cleansing measures.

Contact

contact@malinn.fr
https://macolobox.com

MedInsights

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Soham Saha
Co-founder & CEO
Victor Hannothiaux
Co-founder & CTO
Dimitrije Milunov
Clinical Scientist
Manish Sarkar
Clinical Scientist
Hippolyte Moulle
Data Scientist
Antoine Hazart
Data Scientist

Activity
Medinsights empowers healthcare organizations with real-time data on rare diseases and oncology. We help make smarter decisions, fueling innovation & partnerships. We offer innovative solutions to track, and analyze data: a 1-stop platform solution empowering your strategies in cutting-edge innovation and partnerships. Our team has experience in the healthcare industry and are passionate about building custom-designed analytics and visualizations specific to the client needs.



Contact
soham.saha@medinsights.fr
www.medinsights.fr

NeuralTeks

Sector of activity
Medical Technology or scientific instrumentation

Team
Mehdi Nasreddine-Royer
CEO and co-founder.
Master's Degree in Bioinformatics and MBA in Artificial Intelligence Management.
Dr. Souheil Hanoune
CTO and Co-founder.
Doctor in Artificial Intelligence, Cognitive Sciences and Robotics.

Activity
NeuralTeks is the publisher of a multi-modal SaaS platform that harnesses the power of artificial intelligence to transform the counting and detection of microorganisms in microbiology.



Contact
info@neuralteks.com
www.neuralteks.com

Olva MEDICAL

Sector of activity
Medical Technology or scientific instrumentation

Team
Guillemette Duchateau
CEO et Co-founder
Rémi Dubois
Co-founder
Josselin Duchateau
Co-founder

Activity
Olva Medical is developing a portable and reusable electrophysiology platform. Electrophysiology interventions treat heart rhythm disorders, a major public health issue as they lead to reduced quality of life and increased mortality. Our solution offers more affordable and safer interventions in a context where needs are increasing while financial and material resources are becoming scarce.



Contact
gduchateau@olva-medical.com
https://olva-medical.com

Omena

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Mathilde Neme
CEO
Hahyeon Park
CPO
Michaël Duthilleul
Lead Developer
Laure Blondel
Community Manager

Activity
Omena is a mobile app that helps women manage their perimenopause and menopause symptoms thanks to daily programs built with healthcare practitioners based on nutrition, physical activity, cognitive and behavioural therapies and many other pillars. Today the app is used by 200 000 women monthly.



Contact
mathilde@omena.app
https://www.omena.app

OPGS

Sector of activity
Pharmaceuticals

Team
Rachid Baati
CSO, Co-founder
Guillaume Mezache
Co-founder

Activity
OPGS company results from 18 years of fruitful collaboration between the CNRS and the Army Biomedical Research Institute (IRBA).
We are developing innovative antidotes for nerve agent poisoning thanks to a technological breakthrough. The antidote developed will bring an effective solution to the market compared to the current standard. Therefore, it will save the life of people intoxicated by organophosphorous chemical warfare agents (VX, sarin, soman, tabun) or pesticides (paraoxon).

Contact
rachid.baati@unistra.fr

OPTIDRUGS

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Déborah Hirt
Founder
Valentin Constant
Co-founder

Activity
The service is a SaaS solution, intended for clinicians, which allows the adaptation of anti-infective treatments at the patient's bedside, by predicting the optimal dose of drugs to be administered at initiation and during treatment. The tool takes into account the characteristics of the molecule, the patient and the pathogen and uses algorithms for target selection and dose modification to simply define the optimal dose in each situation (critical care, renal replacement therapies).

Contact
deborah.hirt@aphp.fr

Sector of activity
Pharmaceuticals

Team
Alexandre Santinho
CEO
Marine Moutia
COO
Abdou-Rachid Thiam
CSO

Activity
Oria Bioscience, a spin-off from ENS-PSL, is developing an innovative process to extract cellular organelles (such as lysosomes and mitochondria). These organelles contain therapeutic targets of interest across a wide range of therapeutic areas. At Oria, we purify 1 million organelles per hour, making our process compatible with high-throughput screening technologies. We accelerate organelle testing for Drug Discovery by a factor of 200 and reduce the attrition rate in clinical phases.

Contact
asantinho@oriabs.com
https://www.oriabs.com

Sector of activity
Diagnostics and biomarkers

Team
Marwan Touati
Co-founder
President & CEO
Hang-Phuong Pham
Co-founder
Chief Datascience Officer
Valentin Quiniou
Co-founder
Chief Scientific Officer

Activity
Parean Biotechnologies is a company expert of deep immune phenotyping, and omics datascience, in bulk or single process. As service provider, Parean support academics, biotechs, pharmaceutical industries or CRO. We adress several therapeutic areas, such as oncology, auto-immune diseases or neurology.
Parean Biotechnologies runs several programs, to develop innovative products and services, through partnerships, in immuno-oncology and organ transplantation.

Contact
contact@pareanbiotech.fr
www.pareanbiotech.fr

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Damien Forest
CEO/CTO
Rian Touchent
Chief Scientific Officer
Mikael Chelli
Co-product Owner
Nadège Alavoine
AI Lead
Christian Hein
Business Advisor Sales DACH
Maxime Cavrois
CBO


Activity
We provide a multi-channel (web, smartphone, telephony, physical consultation) and integrated (Espace Santé, medical software) AI suite that enables practitioners to reduce their administrative time, improve the quality of therapeutic follow-up, and accelerate data collection for clinical studies.

Contact
damien.forest@praxysante.fr
https://praxysante.fr & https://praxy.ai

Sector of activity
Diagnostics and biomarkers

Team
Paul Hérent
CEO
Pierre Manceron
CTO

Activity
Raidium develops the first-ever radiological foundation model, as the "GPT" of radiology. This new generation of AI will enable the building of an imaging biomarker factory for both clinical practice and research, to tackle the complexity of precision medicine.



Contact
contact@raidium.eu
https://www.raidium.eu

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Pr. Hang-Korng EA
Co-founder
Dr. Sharon Abiven
Co-founder
Perrine Courtois
CEO

Activity
We develop a complete solution to enable expert care for all patients with chronic rheumatological diseases, combining remote monitoring, self-care tools and therapeutic education.
Find our first service dedicated to gout, on appligoutte.io

Contact
https://rheumacare.io
https://appligoutte.io

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Armelle Roussac
CEO
Pr. Nathalie Kubis
Medical Director
David Holcman
Scientific Director
Daniel Korkotyan
Technical Director

Activity
SignalMed+ develops intelligent algorithmic solutions in the field of prediction of different brain states from the electroencephalographic signal.
The two fields of application are coma and anesthesia. The proposed solutions will allow the prediction of the cerebral prognosis of the patient in coma, an optimal piloting in real time of the drugs used in anaesthesia and the prediction of the possible post-operative complications of anaesthesia.

Contact
armelle.roussac@signalmedplus.com
www.SignalMedPlus.com

Spotlight Medical

Sector of activity
Diagnostics and biomarkers

Team
Sylvain Berlemont
President, CEO
Marvin Lerousseau
CTO
Grégoire Gessain
CMO

Activity
Spotlight Medical is a precision medicine company dedicated to curing cancer through a deep understanding of each patient's unique disease. We develop advanced AI tests that optimize treatment selection by leveraging decades of patient data. This ensures personalized, effective care, significantly improving patient outcomes and quality of life. By closely collaborating with physicians, we create impactful tests addressing critical unmet clinical needs, opening a new era in cancer care.

Contact
contact@spotlightmedical.com
spotlightmedical.com

V4C

Sector of activity
Pharmaceuticals

Team
Joël Calmet
Interim CEO
Brad Schneider
Future CEO
Flor Batin
PMO
Anavaj Sakuntabhai
CSO
Etienne Simon-Lorière
Sr SO

Activity
Dengue is a viral disease transmitted by the Aedes mosquito that puts 2.5 billion people at risk. More than 10 years of research from the Institut Pasteur have enabled V4C to develop the first dengue vaccine for the public sector that is compatible with the vaccine regimens of endemic countries. This innovative vaccine aims to trigger an exclusively cellular immunity, thus preventing the risk of ADE. The project won the ILAB BPI-France 2020 Grand Prize.

Contact
joel.calmet2@gmail.com
florbatinpro@gmail.com
www.v-4-c.com

V4cure

Sector of activity
Pharmaceuticals

Team
Dr. Sonia Escaich
CEO
Dr. Nicolas Gilles
Co-founder
Nabil Gharios
Co-founder
Dr.Thierry Verrechia
CTO
Henry Dorbes
DAF

Activity
Our activity is based on research done at CEA, to identify new therapeutic molecules derived from animal toxins. Our goal is to develop a pipeline of innovative biopharmaceuticals, derived from venoms to treat diseases of the cardio-renal axis, with a high medical need. The first asset of V4Cure is the V4C232 molecule which is a new class of aquaretic molecule to treat water inbalance disorders, and hyponatremia as a first indication and rare polycystic kidney diseases as second indication.

Contact
sonia@v4cure.com
www.v4cure.com

VISIONERVES

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Sabine Sarnacki
Medical Expert
Isabelle Bloch
Scientific Expert
Pietro Gori
Scientific Expert
Juan Pablo de la Plata
CEO
Giammarco La Barbera
CTO

Activity
IMAG2 offers an innovative software solution for 3D digital modelling of the patient from MRI images including the nerves. It is based on artificial intelligence methods that make it suitable for routine use, thanks to its speed of execution and its suitability for surgeons' needs. It is a tool for surgical planning, communication with patients, but also for intraoperative guidance and training for young doctors and surgeons.

Contact
sabine.sarnacki@aphp.fr
isabelle.bloch@sorbonne-universite.fr
https://visionerves.com

VIV ADJU

Sector of activity
Pharmaceuticals

Team
Dr. Rose Ann Padua
President
Dr. Thierry Huet
CEO

Activity
VivAdju is a Biopharmaceutical company pioneering the development of innovative immunotherapy drugs to prevent cancer relapse. VivAdju's approach is unique and universal because it has the potential to be effective in many types of cancer. In less than 3 years, VivAdju will be able to provide evidence of the therapeutic effectiveness of its first drug candidate in humans and hopes to rapidly become a major player in this market segment.

Contact
roseann.padua@vivadju.com
thierry.huet@vivadju.com
www.vivadju.com



Business nursery companies

- Pharmaceuticals
- Diagnostics and biomarkers
- Medical Technology or scientific instrumentation
- E-Health / Software & Mobile Apps / Connected Places & Objects
- Proximity services to patients and health professionals

BIOMUNEX pharmaceuticals

Sector of activity
Pharmaceuticals

Team
Pierre-Emmanuel Gerard
President & CEO
Simon Plyte
CSO

Activity
BIOMUNEX is a biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive therapeutics in oncology, thanks to its proprietary BiXAb® bi- and multi-specific antibody platform. BIOMUNEX is developing a disruptive biological approach, the «BiXAb-MAIT engagers», that redirect MAIT cells to kill cancer cells, and could become a true game changer in the treatment of cancer patients.

Contact
s.plyte@biomunex.com
pe.gerard@biomunex.com
www.biomunex.com

EG 427
PINPOINT GENE THERAPY

Sector of activity
Pharmaceuticals

Team
Philippe Chambon
MD, Ph.D., CEO
Alberto Epstein
Ph.D., CSO
Samuel Salot
PhD, CBO
Don Haut
Ph.D., VP Research
Teddy Jegu
Director of Vectorology
Mikael Contrastin
MSc&T, VP Strategy & Engineering

Pr. François Giuliano,
Pr. Pierre Denys
Scientific Co-founders
MD, PhD

Activity
Taking advantage of Herpes Simplex Virus 1 (HSV-1) natural lifelong latency in peripheral neurons, EG 427 ensures with its highly selective non-replicative vector platform, a durable expression of large transgenes to treat, in the long run, patients with severe, chronic, and localized diseases, starting with peripheral nervous system disorders.



Contact
info@eg427.com
www.eg427.com

egle Tx

Sector of activity
Pharmaceuticals

Team
Dr. Vincent Brichard
CEO
Dr. Bernard Vanhove
CDO
Dr. Monica Gostissa
CSO
Dr. Reno Winter
CTO

Activity
Egle Therapeutics is an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immunosuppressive Treg cells (Tregs) for oncology and autoimmune diseases. Egle's fundamental approach is based on a platform for the discovery of novel solid tumor-specific Treg targets, coupled with specific modulators of Treg immunosuppressive activity, also known as Treg starvers or Treg engagers.

Contact
contact@egle-tx.com
www.egle-tx.com

EMGLEV THERAPEUTICS

Sector of activity
Pharmaceuticals

Team
Christelle Masdeu
CEO, Co-founder
Sandrine Moutel
CSO, Co-founder
Franck Perez
Board Member and Scientifc Advisor, Co-founder
Jean-Christophe Rain
Board Member and Scientifc Advisor, Co-founder
Nathalie Roders
Staff Scientist

Activity
Emglev Therapeutics' mission is to develop immunotherapies for the treatment of solid tumors with unmeet needs by leveraging its proprietary technologies allowing the selection of next generation synthetic antibodies.
The Company aims to become a leader in the development of innovative immunotherapies for the treatment of solid tumors and other pathologies such as inflammatory and infectious diseases.

Contact
christelle.masdeu@emglev-therapeutics.com
https://www.emglev-therapeutics.com

exeliom biosciences

Sector of activity
Pharmaceuticals

Team
Benjamin Hadida
CEO & Co-founder

Activity
Exeliom Biosciences is developing a new generation of immunotherapies based on therapeutic targets that play a critical role in our innate immunity. Our lead candidate, EXL01, is evaluated in Phase 1/2 clinical trials in 3 therapeutic areas: IBD, immuno-oncology and infectious diseases. EXL01, a single-strain live biotherapeutic product, carries unique effectors promoting a distinct and potent immuno-modulatory signal. EXL01 also promotes antitumor efficacy of anti-PD-L1 therapies.



Contact
bhadida@exeliombio.com
www.exeliombio.com

FREMA

Sector of activity
Medical Technology
or scientific instrumentation

Team
Jean-Philippe Wolf
Founder
Romain Wolf
CEO & Founder

Activity
Infertility issues have become a growing public health concern. Since the invention of ICSI in 1992, no technology discovery has improved the outcomes of Assisted Reproductive Technology (ART) procedures. In response to this challenge, FREMA is developing a molecule to enhance the outcomes of these procedures. It is currently undergoing a multicenter randomized clinical trial, with results expected in 2026.



Contact
contact@raidium.eu
https://www.raidium.eu

Sector of activity

Diagnostics and biomarkers

Team

Ludovic Lecointre
CEO
Bruno Osmanski
CTO
Djamel Zekri
CM & SO

Activity

Iconeus develops and markets Iconeus One, a functional and vascular neuro-imaging platform for preclinical research. Iconeus One benefits from innovative ultra-fast ultrasound technology and allows super-resolution vascular imaging, real-time neuro-functional imaging and mapping of cerebral connectivity.
Numerous clinical applications are under investigation, particularly in neurological resuscitation, neurosurgery and in monitoring the neurodevelopment of the newborn.



Contact

ludovic.lecointre@iconeus.com
www.iconeus.com

Sector of activity

E-Health / Software & Mobile Apps / Connected Places & Objects

Team

Bogdan Nedelcu
CEO & Founder
Thomas Gelot
Adviser
Julien Erdogan
Product Engineer
Marwan Ghanem
Research Engineer AI
Charles-Emmanuel Dias
Research Engineer AI

Activity

Our IoT platform allows hospitals to improve and optimize their operations and reduce costs through real-time geolocation of equipment and patients. In addition to enabling healthcare staff to find equipment and patients in real time, the platform automatically compiles location data into KPIs (equipment utilization rates, patient waiting time, processes) accessible through easy-to-read dashboards for hospital managers.



Contact

bogdan@intelligentlocations.io
support@intelligentlocations.io
www.intelligentlocations.fr

Sector of activity


Diagnostics and biomarkers


Team

Cyril Gilbert
CEO
Claude Nogues
Scientific Director

Activity

Kimialys is pushing further the limits of biosensing, enabling the development of tomorrow's diagnostics and therapeutics. The company leverages a patented coating technology applied to nanoparticles and chips, enhancing the sensitivity, specificity and reproducibility of diagnostic tests and in vitro analyses. Kimialys' current offering ranges from the production of coated nanoparticles for diagnostic test developers to the analysis of biomolecular interactions for drug discovery laboratories.





Contact

cyril.gilbert@kimialys.com
https://www.kimialys.com

Sector of activity

E-Health / Software & Mobile Apps / Connected Places & Objects

Team

Alexandre Parpaleix
Chairman, Medical Director
Aïssa Khelifa
CEO
Peggy Séjourné
COO
Ronan Riochet
CTO
Malo Huard
CSO

Activity

Our mission: opening new horizons for medical imaging. We respond to new challenges in medical imaging by creating dedicated AI solutions integrated into radiologists' daily routine. Based on a focused use of Deep Learning, we help radiologists make faster diagnoses, better manage patients' workflows, and focus even more efficiently on patients.

OUR AI DOES NOT REPLACE RADIOLOGISTS, IT MAKES THEM IRREPLACEABLE.



Contact

contact@milvue.com
www.milvue.com

Sector of activity

E-Health / Software & Mobile Apps / Connected Places & Objects

Team

Pierre Saudin
Co-founder & CEO
Paul Jehanno
Co-founder & CTO
Dr. Paul Blanc-Durand
Co-founder & CMO

Activity

Using Deep Learning, PAIRE supports doctors in the interpretation of nuclear medicine examinations, which are the standard for diagnosis and follow-up in cancerology. PAIRE's AI helps save time, improve the accuracy of measurements, avoid errors and provide access to new key indicators in clinical routine for a better care of patients. PAIRE aims to solve the challenges of tomorrow's nuclear medicine.

Contact

pierres@paire.tech
www.paire.tech

Sector of activity

Pharmaceuticals

Team

Robert Marino
CEO
Jean Philip Piquemal
CSO
Pr. Matthieu Montes
Co-founder
Pr. Pengyu Ren
Co-founder
Pr. Jay Ponder
Co-founder
Dr. Louis Lagardère
Co-founder

Activity

Deeptech startup specializing in the discovery of novel treatments using molecular simulation and AI, accelerated by hybrid HPC and quantum computing. Thanks to our in silico drug discovery platform, ATLAS, and in collaboration with biopharmas, we accelerate the discovery and validation of a new drug candidates while reducing associated costs.
We leverage the power of quantum to design better treatments for every target and every patient.

Contact

contact@qubit-pharmaceuticals.com
https://qubit-pharmaceuticals.com


ROBEAUTÉ

Sector of activity
Medical Technology
or scientific instrumentation

Team
Bertrand Duplat
CEO
Joana Cartocci
COO

Activity
Robeauté is developing a neurosurgical modular microrobotic device to intervene seamlessly in the brain extracellular matrix. With 3D motility and real-time data collection, the device is capable of diagnosing brain diseases, delivering therapies and monitoring.





Contact
hello@robeaute.com
www.robeaute.com

smartimmune

Sector of activity
Pharmaceuticals

Team
Karine Rossignol
CEO and Co-founder
Marina Cavazzana
Co-founder and Strategic translational advisor
Olivier Nègre
Chief Scientific Officer
Pierre Heimendinger
Chief Technical Officer
Jéremy Gaillard
Chief Financial and Business Officer

Activity
Smart Immune is a French biotechnology company developing ProTcell, a thymus-empowered T cell progenitor platform to rapidly re-arm the immune system against cancer and infection. The company aims to radically improve outcomes for patients in hematology and immuno-oncology.
SMART101 is in Phase I/II trials for patients with acute leukemia or SCID, in the EU and the US. Additional clinical applications are planned to be evaluated in combination with innovative cancer therapies.



Contact
info@smart-immune.com
www.smart-immune.com

Spimed-AI

Sector of activity
E-Health / Software & Mobile Apps / Connected Places & Objects

Team
Jean-François Paul
Co-Founder & Chairman
Théophile Adouard
Director of Operations
Henri Giroussens
CTO
Romane Thu
Full-stack engineer
Aurèle Duparc
Full-stack engineer
Yassine Ougoudad
Qara Manager
Loïc Paul
Legal Director
François Brunhes
Dev-Ops Engineer
Bapiste Esteban
Image processing research engineer
Florian Muller
Data Scientist
Sébastien Monnot
Product Manager

Activity
Founded in 2019, Spimed-AI is developing an IA based coronary artery image analysis solution that provides predictive, diagnostic and therapeutic information to optimize patient management based on CCTA (cardiac computed tomography angiography) images.
By enabling more efficient management, CorEx reduces loss of chance, saves physician time and lowers the cost of patient management.

Contact
contact@spimed-ai.com
www.spimed-ai.com

Spore.Bio

Sector of activity
Medical Technology
or scientific instrumentation

Team
Raji Amine
CEO
Mistretta Maxime
CTO
Tazi Mohamed
COO

Activity
Current technologies to track possible contamination all have the same issues: they are extremely long and inherently restrictive. Spore.Bio's aim is to make the world a safer place by developing a new generation of microbiological tests. Their method is using physics and AI advanced technologies, to detect and quantify bacteria within seconds while conventional methods takes up to 5 days. First prototypes have been deployed on the shop floor in May 2024.



Contact
admin@spore.bio
www.spore.bio

surge

Sector of activity
Diagnostics and biomarkers

Team
Julien Hédou
CEO & Co-founder
Valentin Picot
COO & Co-founder
Franck Verdonk
CMO & Co-founder
Dominique Blanchard
CTO
Benjamin Choisy
PM & Co-founder
Brice Gaudillière
Co-founder
Dyani Jones
Co-founder

Activity
Founded with the goal of revolutionizing precision medicine, Surge is an innovative company specializing in in-depth understanding of the immune system using AI. With PreCyte®, for predicting the risk of postoperative complications, and its premier laboratory, SurgeLab™, for acquiring individualized immune signatures, the company aims to become a leader in precision immune analysis.



Contact
jhedou@surge.care
www.surge.care



Business hotel companies

- Pharmaceuticals
- Diagnostics and biomarkers
- Medical Technology or scientific instrumentation
- E-Health / Software & Mobile Apps / Connected Places & Objects
- Proximity services to patients and health professionals

endodiag

Let's change their lives

Sector of activity


Diagnostics and biomarkers

Team

Cecile Real
CEO
Karine Mignon Godefroy
VP Head of R&D

Activity

Endometriosis is a complex disease that affects 10% of women of child-bearing age (180 million women worldwide) and negatively impacts their quality of life (pain, bleeding, infertility, chronic fatigue...). Endodiag develops innovative products and services to provide healthcare professionals with new solutions to diagnose earlier and more easily this disease while improving patient management.



Contact

contact@endodiag.com
www.endodiag.com

Geno Splice

Sector of activity

E-Health / Software & Mobile Apps / Connected Places & Objects

Team

Marc Rajaud
Co CEO & CFO
Pierre de la Grange
Co CEO & CSO
Olivier Ariste
Senior analyst
Noémie Robil
Senior analyst
Ariane Jolly
Analyst
Wail Zeintouni
Analyst
Rebecca Goulancourt
Analyst

Activity

GenoSplice, a bioinformatics services company, analyzes the regulation of gene expression and exhibits proven expertise in the analysis of multi-omics data. Our field of expertise allows the study of various data (transcriptome, genome, regulome, methylome, histone modifications, etc.) and can be applied to the study of many biomedical fields. Particular attention is given to the follow-up of projects till the end and to communication with partners.

Contact

contact@genosplice.com
www.genosplice.com

HiFiBiO THERAPEUTICS

Sector of activity

Pharmaceuticals

Team

Sami Ellouze
CEO

Activity

HiFiBiO Therapeutics, is an emerging multinational in the field of biotherapies using the human immune system to fight cancers and autoimmune diseases. Thanks to our single-cell, high-throughput screening technology and biological expertise, we have the ability to accelerate the discovery and development of therapeutic antibodies, through innovative industrial and academic collaborations, to make them accessible to patients.



Contact

s.demoulin@hifibio.com
www.hifibio.com

light in derm

REGENERATIVE SKIN CARE

Sector of activity

Medical Technology
or scientific instrumentation

Team

Géraldine Decaux
CEO & Founder
Jean-Alexis Grimaud
Scientific Director
Thierry Demeure
Business Director
Margaux Cardera
R&D Manager
Olivier Lisowski
Product Manager
Anthony Dulieux
Digital Manager
Lucile Chassang
Industrialisation Manager
Marion Tostain
Product Chief
Amandine Zaurin
Key Account Manager
Solène Jean
Customer Care

Activity

InDerm develops home use device for dermatologic and cosmetic applications. Inderm technology combines visible and infra-red light with photo-active ingredients to improve skin.
Inderm technology triples skin repair capacities. A broad range of applications are expected from skin rejuvenation to wound healing.

Contact

geraldine.decaux@inderm.com
www.lightinderm.com

METAFORA biosystems

Sector of activity

Diagnostics and biomarkers

Team

Vincent Petit
Co-founder & CEO
Romain Kaspereit
General Manager & CFO
Luc d'Auriol
Co-founder & Chairman

Activity

Metafora is developing a unique platform able to detect and characterize single cell energetics to establish a timely and precise diagnosis (IVD market), and to optimize therapeutic cells' metabolic fitness. Our first CE-IV test is entering on the market, and promising R&D projects are ongoing in oncology and cell therapies. We also develop METAflow, a breakthrough software for automated cytometry data analysis powering the platform; the software is launched on the research market in 2022.



Contact

contact@metafora-biosystems.com
www.metafora-biosystems.com

peptinov

Sector of activity

Pharmaceuticals

Team

René Azoulai
CEO
Pr. Jean-François Zagury
Founder
Hervé Do
CFO
Jean-Pierre Salles
CSO

Activity

Peptinov develops an innovative therapeutic strategy, active immunotherapy targeting self-proteins, with several immunogenic peptide candidates in development in its R&D pipeline. Peptinov targets chronic low-grade inflammation with its anti-IL-6 immunotherapy, which is its most advanced product.
This anti-IL-6 immunotherapy is currently being evaluated in a phase 1 clinical trial in patients suffering from inflammatory knee osteoarthritis.



Contact

contact@peptinov.fr
www.peptinov.fr



FOUNDING MEMBERS:

Université Paris Cité

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

ESSEC BUSINESS SCHOOL

CentraleSupélec

Inserm

WITH THE SUPPORT OF:

MINISTÈRE DE L'ENSEIGNEMENT SUPÉRIEUR, DE LA RECHERCHE ET DE L'INNOVATION
Liberté Égalité Fraternité

INVESTIR L'AVENIR

PARIS INNOVATION

PARIS

Région îledeFrance

bpifrance

RIVP

RÉPUBLIQUE FRANÇAISE
Liberté Égalité Fraternité

anr agence nationale de la recherche

FRANCE 2030

Paris Biotech Santé

Faculté de Médecine / Site Cochin / Université Paris Cité
24, rue du Faubourg Saint-Jacques
75014 Paris

contact@parisbiotechsante.org

www.parisbiotechsante.org

@ParisBiotech

https://fr.linkedin.com/company/paris-biotech-sante

KEY FIGURES

incubator 2013-2023

104 M€ public funds

79 active companies

112 projects

109 patents

103 created companies

1386 jobs

228 M€ raised funds

survival rate
- **93%** up to 3 years
- **80%** up to 5 years
- **71%** up to 10 years

business nursery 2007-2023

332 M€ public funds

53 active companies

1832 patents

64 hosted companies

1924 jobs

1881 M€ raised funds

survival rate
- **100%** up to 3 years
- **93%** up to 5 years
- **86%** up to 10 years

6 initial public offering
- ACTICOR BIOTECH
- OSE IMMUNOTHERAPEUTICS
- GENOMIC VISION
- PHARNEXT
- DBV TECHNOLOGIES
- THERACLION

Paris Biotech Santé